Slingshot members are tracking this event:

Takeda's(TAK) CABOMETYX (cabozantinib) Approved in Japan for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details
Takeda’s application is based on the results of two clinical trials in patients with advanced HCC who had received prior systemic therapy: CELESTIAL (XL184-309), a global, randomized, placebo-controlled, double-blind phase 3 clinical trial, and Cabozantinib-2003, a phase 2 clinical trial conducted in Japan. The CELESTIAL trial was the basis for the CABOMETYX approvals in the U.S. and the EU for the treatment of patients with HCC who have been previously treated with sorafenib.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 27, 2020
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Unresectable Hepatocellular Carcinoma